This is exemplified by the combination of Lenvatinib-anti-PD-1/PD-L1 in a pre-clinical immunocompetent murine model, in which Lenvatinib monotherapy increased the infiltration of TAMs, Tregs, and polymorphonuclear MDSCs (PMN-MDSCs), while combined therapy showed a significantly decreased infiltration by PMN-MDSCs, which, in turn, was associated with an improvement in tumor shrinkage and survival [35]. The gene discussed is PDCD1; the disease is neoplasm.